Harmonix is a French deeptech developing a next-generation platform for targeted, repetable and non-invasive CNS delivery of nucleic acid therapeutics. Combining focused ultrasound, engineered microbubbles and proprietary lipid formulations, we collaborate with pharmaceutical and biotechnology partners to unlock new opportunities for siRNA, mRNA, ASO, circular RNA and other advanced nucleic acid therapies.

StemSight develops off-the-shelf induced pluripotent stem (iPS) cell therapies to restore vision in patients with severe corneal diseases. Its lead program, STE-101, targets bilateral limbal stem cell deficiency using a scalable, hypoimmunogenic iPS cell platform designed to make cell therapies more accessible and cost-effective. The company's long-term vision is to become a leader in regenerative ophthalmology through a pipeline of allogeneic cell therapies.

CureAge Therapeutics is pioneering a new generation of genetic medicines designed to tackle peripheral nerve diseases at their source. Starting with Neurofibromatosis type 1 (NF1), a debilitating genetic condition affecting more than three million people worldwide, CureAge is developing a first-in-class platform that uses lipid nanoparticles to deliver therapeutic genetic material directly to the cells driving tumour growth. With the potential to halt, reverse and even prevent NF1 tumours, CureAge is moving beyond symptom management towards lasting, transformative cures.

Korecyte Bio is a UK-based biotechnology company developing integrated in vivo CAR-T therapies for solid cancers. Its lead programme, KOR101, is designed to generate CAR-T cells directly within patients while combining HypoxiCAR tumour-restricted activation, broad tumour targeting and co-armouring in a single therapeutic approach. Korecyte aims to overcome the biological barriers that have limited CAR-T efficacy in solid tumours and make next-generation cell therapy more scalable, precise and accessible.

Venture Associate at UCB Ventures

Rahul invests in innovative biotechnology companies at UCB Ventures, supporting investments in breakthrough therapeutics with expertise spanning life sciences, strategy, venture capital and healthcare finance.

Principal at Invivo Partners

As Principal at Invivo Partners, she invests in pioneering healthcare companies and works closely with founders, bringing extensive experience in biotech innovation, venture capital and startup evaluation.

Investor at Delin Ventures

Matt invests in cell therapy companies and enabling technologies at Delin Ventures, combining experience in venture capital, corporate strategy and biotech operations to support emerging innovators.